BeiGene’s PD-1 drug approved in EU for first-line oesophageal cancer treatment
The European Commission’s decision is based on two Phase III trials where Tevimbra plus chemotherapy improved overall survival.
Cancer
Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time
AbbVie’s Elahere wins European approval for certain ovarian cancers
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
Uppsala and KTH Royal develop antibody for potential cancer treatment
Alpha-9 becomes latest radiopharma to secure funds with $175m Series C
ImmunoPrecise touts potential of rabbit monoclonal antibodies in oncology
FDA approves Astellas’ VYLOY for gastric cancer treatment
